07:35 AM EDT, 10/07/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Tuesday its phase 3 trial of baxdrostat in patients with treatment-resistant hypertension met its primary endpoint.

The investigational drug showed a statistically significant and clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure at 12 weeks, compared with placebo, according to AstraZeneca ( AZN ).

The company said the drug achieved efficacy for 24 hours, including early morning when hypertensive patients face a higher risk of cardiovascular events. It was also generally well tolerated, with a safety profile consistent with a previous trial, AstraZeneca ( AZN ) said.

The company said it will share the data with regulatory agencies globally and make a presentation at a conference in November.